Role of catecholamines in the ketonemic response to somatostatin in normal man.
In order to determine if a rise of circulating catecholamines occurs during somatostatin (SRIF) infusion in normal man, and if this increase plays a significant metabolic role, we infused four normal subjects with SRIF (500 micrograms/h) alone or associated with either alpha-(phentolamine) or beta-(propranolol) adrenergic blocking agents. During SRIF infusion, the initial small decrease in blood glucose was followed by a rise of epinephrine from 25-46 ng/liter (range) to 117-143 ng/liter (range) (P less than 0.05) at 80 min and norepinephrine from 204 +/- 16 to 418 +/- 60 ng/liter at 90 min (P less than 0.05). Thereafter, plasma nonesterified fatty acids, blood glycerol, and ketone bodies increased significantly. Phentolamine adjunction modified neither the catecholamines rise, nor the metabolic changes. Propranolol adjunction did not modify the glucose fall and the catecholamine rise, but resulted in blunted increments of fatty acids and glycerol and in an almost complete suppression of the increase of ketone bodies. These results suggest that the enhanced lipolysis and ketogenesis observed during SRIF infusion are not only due to the SRIF-induced insulin deficiency but also in part to a beta-receptor mediated effect of catecholamines.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D004837:Epinephrine / Q000097:blood*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007657:Ketone Bodies / Q000097:blood*; D008297:Male; D009638:Norepinephrine / Q000097:blood*; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012016:Reference Values; D013004:Somatostatin / Q000494:pharmacology*
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007657:Ketone Bodies; D013004:Somatostatin; D011433:Propranolol; D006854:Hydrocortisone; D009638:Norepinephrine; D004837:Epinephrine; D010646:Phentolamine